{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:27:28Z","timestamp":1792099648683,"version":"4.4.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.amjms.2020.07.011","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T11:54:22Z","timestamp":1594382062000},"page":"641-649","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["When and How to Diagnose Fabry Disease in Clinical Pratice"],"prefix":"10.1016","volume":"360","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1461-7733","authenticated-orcid":false,"given":"Martin","family":"Michaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wladimir","family":"Mauhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Belmatoug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roselyne","family":"Garnotel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiya","family":"Bedreddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Catros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ancellin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lidove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Gaches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2020.07.011_bib0001","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.amjms.2020.07.011_bib0002","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1399-0004.2011.01718.x","article-title":"Fabry disease \u201cThe New Great Imposter\u201d: results of the French Observatoire in Internal Medicine Departments (FIMeD)","volume":"81","author":"Lidove","year":"2001","journal-title":"Clin Genet"},{"key":"10.1016\/j.amjms.2020.07.011_bib0003","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.amjms.2020.07.011_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2009.12.022","article-title":"Department-related tasks and organ-targeted therapy in Fabry disease: an interdisciplinary challenge","volume":"123","author":"Weidemann","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.amjms.2020.07.011_bib0005","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/gim.2016.55","article-title":"Is it Fabry disease?","volume":"18","author":"Schiffmann","year":"2016","journal-title":"Genet Med"},{"key":"10.1016\/j.amjms.2020.07.011_bib0006","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/ndt\/gfq306","article-title":"Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy","volume":"26","author":"Sanchez-Ni\u00f1o","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjms.2020.07.011_bib0007","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.amjms.2020.07.011_bib0008","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1073\/pnas.85.11.3903","article-title":"Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3\u2019 untranslated region","volume":"85","author":"Bishop","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.amjms.2020.07.011_bib0009","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin Genet"},{"key":"10.1016\/j.amjms.2020.07.011_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112188","article-title":"Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease","volume":"9","author":"Mauer","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.amjms.2020.07.011_bib0011","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/jhg.2011.31","article-title":"Fabry-database.org: database of the clinical phenotypes, genotypes and mutant \u03b1-galactosidase A structures in Fabry disease","volume":"56","author":"Saito","year":"2011","journal-title":"J Hum Genet"},{"key":"10.1016\/j.amjms.2020.07.011_bib0012","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1651-2227.2005.tb02119.x","article-title":"Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey","volume":"94","author":"Schaefer","year":"2005","journal-title":"Acta Paediatr"},{"key":"10.1016\/j.amjms.2020.07.011_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/518036a","article-title":"Lyon (1925\u20132014)","volume":"518","author":"Rastan","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.amjms.2020.07.011_bib0014","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00439-011-1013-x","article-title":"Mary Lyon and the hypothesis of random X chromosome inactivation","volume":"130","author":"Harper","year":"2011","journal-title":"Hum Genet"},{"key":"10.1016\/j.amjms.2020.07.011_bib0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.amjms.2020.07.011_bib0016","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.amjms.2020.07.011_bib0017","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936 919G>A (IVS4919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.amjms.2020.07.011_bib0018","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2119\/molmed.2012.00002","article-title":"Fabry Disease: incidence of the Common Later-Onset \u03b1-Galactosidase A IVS4 919G\u2192A Mutation in Taiwanese Newborns\u2014Superiority of DNA-Based to Enzyme-Based Newborn Screening for Common Mutations","volume":"18","author":"Chien","year":"2012","journal-title":"Mol Med"},{"key":"10.1016\/j.amjms.2020.07.011_bib0019","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1042\/EBC20170053","article-title":"The genetic basis of disease","volume":"62","author":"Jackson","year":"2018","journal-title":"Essays Biochem"},{"key":"10.1016\/j.amjms.2020.07.011_bib0020","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","article-title":"Fabry disease and the skin: data from FOS, the Fabry outcome survey","volume":"157","author":"Orteu","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.amjms.2020.07.011_bib0021","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/0002-9343(65)90086-0","article-title":"Angiokeratoma corporis diffusum universale (Fabry)","volume":"39","author":"Wallace","year":"1965","journal-title":"Am J Med"},{"key":"10.1016\/j.amjms.2020.07.011_bib0022","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.32.5.498","article-title":"Fabry disease: impaired autonomic function","volume":"32","author":"Cable","year":"1982","journal-title":"Neurology"},{"key":"10.1016\/j.amjms.2020.07.011_bib0023","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1742-1241.2006.01061.x","article-title":"Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey","volume":"60","author":"Lidove","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.amjms.2020.07.011_bib0024","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.39300","article-title":"Characterization of small fiber pathology in a mouse model of Fabry disease","volume":"7","author":"Hofmann","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.amjms.2020.07.011_bib0025","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-11-61","article-title":"Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel","volume":"11","author":"Burlina","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.amjms.2020.07.011_bib0026","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ymgme.2012.03.010","article-title":"Small fiber neuropathy in Fabry disease","volume":"106","author":"Biegstraaten","year":"2012","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.amjms.2020.07.011_bib0027","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.amjms.2020.07.011_bib0028","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents","volume":"162","author":"Ries","year":"2003","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.amjms.2020.07.011_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0148316","article-title":"No Fabry Disease in Patients Presenting with Isolated Small Fiber Neuropathy","volume":"11","author":"de Greef","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.amjms.2020.07.011_bib0030","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s00415-012-6619-y","article-title":"FabryScan: a screening tool for early detection of Fabry disease","volume":"259","author":"Arning","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.amjms.2020.07.011_bib0031","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1076\/opge.24.3.129.15609","article-title":"Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients","volume":"24","author":"Orssaud","year":"2003","journal-title":"Ophthalmic Genet"},{"key":"10.1016\/j.amjms.2020.07.011_bib0032","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/bjophthalmol-2014-306433","article-title":"Cornea verticillata supports a diagnosis of Fabry disease in non-classical phenotypes: results from the Dutch cohort and a systematic review","volume":"100","author":"Tol","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.amjms.2020.07.011_bib0033","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/aos.12588","article-title":"Ophthalmic experience over 10 years in an observational nationwide Danish cohort of Fabry patients with access to enzyme replacement","volume":"93","author":"Fledelius","year":"2015","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.amjms.2020.07.011_bib0034","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s12551-018-0432-5","article-title":"Anderson-Fabry disease in heart failure","volume":"10","author":"Akhtar","year":"2018","journal-title":"Biophys Rev"},{"key":"10.1016\/j.amjms.2020.07.011_bib0035","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0735-1097(02)02380-X","article-title":"Cardiac manifestations of Anderson\u2013Fabry disease in heterozygous females","volume":"40","author":"Kampmann","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjms.2020.07.011_bib0036","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular Events in Patients With Fabry Disease","volume":"57","author":"Patel","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjms.2020.07.011_bib0037","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/heartjnl-2014-306782","article-title":"Clinical and genetic predictors of major cardiac events in patients with Anderson\u2013Fabry Disease","volume":"101","author":"Patel","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.amjms.2020.07.011_bib0038","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/hrt.2005.063818","article-title":"The heart in Anderson-Fabry disease and other lysosomal storage disorders","volume":"93","author":"Linhart","year":"2007","journal-title":"Heart"},{"key":"10.1016\/j.amjms.2020.07.011_bib0039","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of Fabry Disease in a Cohort of 508 Unrelated Patients With Hypertrophic Cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjms.2020.07.011_bib0040","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson\u2013Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjms.2020.07.011_bib0041","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/hrt.2010.200188","article-title":"Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study","volume":"97","author":"Hagege","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.amjms.2020.07.011_bib0042","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease Survey","volume":"97","author":"Elliott","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.amjms.2020.07.011_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2017.09.010","article-title":"Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.amjms.2020.07.011_bib0044","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.amjms.2020.07.011_bib0045","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.beem.2014.10.003","article-title":"Fabry disease and the heart","volume":"29","author":"Seydelmann","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.amjms.2020.07.011_bib0046","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jjcc.2007.12.001","article-title":"Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study","volume":"51","author":"Takenaka","year":"2008","journal-title":"J Cardiol"},{"key":"10.1016\/j.amjms.2020.07.011_bib0047","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjms.2020.07.011_bib0048","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/ndt\/gfm848","article-title":"Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy","volume":"23","author":"Ortiz","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjms.2020.07.011_bib0049","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/ndt\/gfp658","article-title":"Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate","volume":"25","author":"T\u00f8ndel","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjms.2020.07.011_bib0050","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease: natural History Data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2020.07.011_bib0051","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ndt\/gfp554","article-title":"End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry","volume":"25","author":"Ortiz","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.amjms.2020.07.011_bib0052","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/01.ASN.0000124671.61963.1E","article-title":"Results of a Nationwide Screening for Anderson-Fabry Disease among Dialysis Patients","volume":"15","author":"Kotanko","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2020.07.011_bib0053","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/BJMMR\/2017\/32156","article-title":"Screening for Fabry Disease among Dialysis Patients in Brazil: findings from the First 18 months of a Nationwide Study","volume":"21","author":"Coutinho","year":"2017","journal-title":"Br J Med Med Res"},{"key":"10.1016\/j.amjms.2020.07.011_bib0054","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype 1","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.07.011_bib0055","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","article-title":"Cerebrovascular Involvement in Fabry Disease","volume":"46","author":"Kolodny","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.amjms.2020.07.011_bib0056","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1161\/STROKEAHA.108.526293","article-title":"Stroke in Fabry Disease Frequently Occurs Before Diagnosis and in the Absence of Other Clinical Events","volume":"40","author":"Sims","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.amjms.2020.07.011_bib0057","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1161\/STROKEAHA.109.558320","article-title":"Frequency of Unrecognized Fabry Disease Among Young European-American and African-American Men With First Ischemic Stroke","volume":"41","author":"Wozniak","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.amjms.2020.07.011_bib0058","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00392-018-1285-4","article-title":"Value of the CHA2DS2-VASc score and Fabryspecific score for predicting new-onset or recurrent stroke\/TIA in Fabry disease patients without atrial fibrillation","volume":"107","author":"Liu","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.amjms.2020.07.011_bib0059","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1212\/WNL.0000000000002673","article-title":"Determinants of white matter hyperintensity burden in patients with Fabry disease","volume":"86","author":"Rost","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.amjms.2020.07.011_bib0060","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.msard.2019.06.008","article-title":"Multiple sclerosis and Fabry disease - diagnostic \"mixup\"","volume":"34","author":"Jura\u0161i\u0107","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.amjms.2020.07.011_bib0061","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.msard.2019.01.040","article-title":"Misdiagnosis of multiple sclerosis in a female heterozygote with Fabry's disease","volume":"30","author":"Berger","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.amjms.2020.07.011_bib0062","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1121","article-title":"Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis","volume":"8","author":"Ugga","year":"2018","journal-title":"Brain Behav"},{"key":"10.1016\/j.amjms.2020.07.011_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116782","article-title":"Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: a cross-sectional study","volume":"412","author":"Russo","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.amjms.2020.07.011_bib0064","article-title":"Vertebrobasilar Dolichoectasia in Fabry Disease","volume":"2","author":"Politei","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.amjms.2020.07.011_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137603","article-title":"Eight-Year Follow-Up of Neuropsychiatric Symptoms and Brain Structural Changes in Fabry Disease","volume":"10","author":"Lelieveld","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.amjms.2020.07.011_bib0066","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/arclin\/acu047","article-title":"Cognitive and Psychological Functioning in Fabry Disease","volume":"29","author":"Sigmundsdottir","year":"2014","journal-title":"Arch Clin Neuropsychol"},{"key":"10.1016\/j.amjms.2020.07.011_bib0067","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10545-007-0708-6","article-title":"Depression in adults with Fabry disease: a common and under-diagnosed problem","volume":"30","author":"Cole","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.amjms.2020.07.011_bib0068","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2350-3-10","article-title":"Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients","volume":"3","author":"Germain","year":"2002","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.amjms.2020.07.011_bib0069","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2350-3-10","article-title":"Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients","volume":"3","author":"Germain","year":"2002","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.amjms.2020.07.011_bib0070","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","article-title":"Gastrointestinal Symptoms in 342 Patients With Fabry Disease: prevalence and Response to Enzyme Replacement Therapy","volume":"5","author":"Hoffmann","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.amjms.2020.07.011_bib0071","first-page":"25","article-title":"Gastrointestinal Phenotype of Fabry Disease in a Patient with Pseudoobstruction Syndrome","author":"Buda","year":"2011","journal-title":"JIMD Rep"},{"key":"10.1016\/j.amjms.2020.07.011_bib0072","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.2174\/13816128113199990347","article-title":"Gastroenterological Complications of Anderson-Fabry Disease","volume":"19","author":"Buda","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.amjms.2020.07.011_bib0073","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/GIM.0b013e31815cb197","article-title":"Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density","volume":"9","author":"Mersebach","year":"2007","journal-title":"Genet Med"},{"key":"10.1016\/j.amjms.2020.07.011_bib0074","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1399-0004.2005.00457.x","article-title":"Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease","volume":"68","author":"Germain","year":"2005","journal-title":"Clin Genet"},{"key":"10.1016\/j.amjms.2020.07.011_bib0075","first-page":"26721","article-title":"Fabry disease, respiratory symptoms, and airway limitation \u2013 a systematic review","volume":"2","author":"Svensson","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.amjms.2020.07.011_bib0076","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","article-title":"Quality of life in patients with Fabry disease: a systematic review of the literature","volume":"10","author":"Arends","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.amjms.2020.07.011_bib0077","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","article-title":"Characterization of Classical and Nonclassical Fabry Disease: a Multicenter Study","volume":"28","author":"Arends","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.amjms.2020.07.011_bib0078","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/jmedgenet-2014-102872","article-title":"Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease","volume":"52","author":"Smid","year":"2015","journal-title":"J Med Genet"},{"key":"10.1016\/j.amjms.2020.07.011_bib0079","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jmedgenet-2013-101857","article-title":"A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance","volume":"51","author":"Tol","year":"2014","journal-title":"J Med Genet"},{"key":"10.1016\/j.amjms.2020.07.011_bib0080","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"10.1016\/j.amjms.2020.07.011_bib0081","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.amjms.2020.07.011_bib0082","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123726","article-title":"Mutations in the GLA Gene and LysoGb3: is It Really Anderson-Fabry Disease?","volume":"19","author":"Duro","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.amjms.2020.07.011_bib0083","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.amjms.2020.07.011_bib0084","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1253\/circj.CJ-19-0110","article-title":"Plasma Globotriaosylsphingosine Level as a Primary Screening Target for Fabry Disease in Patients With Left Ventricular Hypertrophy","volume":"83","author":"Yamashita","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.amjms.2020.07.011_bib0085","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ymgme.2017.06.006","article-title":"Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease","volume":"121","author":"Nowak","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.amjms.2020.07.011_bib0086","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/gim.2018.31","article-title":"Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis","volume":"21","author":"Maruyama","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.amjms.2020.07.011_bib0087","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymgme.2016.10.006","article-title":"Plasma LysoGb3: a useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes","volume":"120","author":"Nowak","year":"2017","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.amjms.2020.07.011_bib0088","article-title":"Diagnostic strategy for Females suspected of Fabry Disease","author":"Balendran","year":"2019","journal-title":"Clin Genet"},{"key":"10.1016\/j.amjms.2020.07.011_bib0089","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cca.2019.10.031","article-title":"\u03b1-Galactosidase A\/lysoGb3 ratio as a potential marker for Fabry disease in females","volume":"501","author":"Baydakova","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.amjms.2020.07.011_bib0090","first-page":"S20","article-title":"Plasma lyso-Gb3 in Fabry disease: helpful distinguishing phenotypes, but not as predictor of organ involvement","volume":"126","author":"Aguiar","year":"2019","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.amjms.2020.07.011_bib0091","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.ymgme.2017.12.278","article-title":"Expanded analysis of Lyso-GB3 analogues and correlation with total Lyso-GB3 and Fabry status in 59 clinical patients","volume":"123","author":"Netzel","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.amjms.2020.07.011_bib0092","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.amjms.2020.07.011_bib0093","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1038\/ki.2008.522","article-title":"Renal manifestations in Fabry disease and therapeutic options","volume":"111","author":"Torra","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.amjms.2020.07.011_bib0094","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.amjms.2020.07.011_bib0095","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/01.md.0000178976.62537.6b","article-title":"The Relationship of Vascular Glycolipid Storage to Clinical Manifestations of Fabry Disease","volume":"84","author":"Gupta","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.amjms.2020.07.011_bib0096","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.cca.2015.10.027","article-title":"Pitfalls in the detection of gross gene rearrangements using MLPA in Fabry disease","volume":"452","author":"Ferri","year":"2016","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.amjms.2020.07.011_bib0097","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10545-017-0127-2","article-title":"Globotriaosylsphingosine (Lyso-Gb) as a biomarker for cardiac variant (N215S) Fabry disease","volume":"41","author":"Alharbi","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.amjms.2020.07.011_bib0098","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.amjms.2020.07.011_bib0099","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10897-013-9613-3","article-title":"Fabry disease practice guidelines: recommendations of the National Society of Genetic Counselors","volume":"22","author":"Laney","year":"2013","journal-title":"J Genet Couns"},{"key":"10.1016\/j.amjms.2020.07.011_bib0100","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ymgme.2018.04.004","article-title":"Therapeutic goals in Fabry disease: recommendations of a European expert panel, based on current clinical evidence with enzyme replacement therapy","volume":"126","author":"Wanner","year":"2019","journal-title":"Mol Genet Metab"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962920303050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962920303050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:38:22Z","timestamp":1757702302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962920303050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":100,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0002962920303050"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2020.07.011","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"When and How to Diagnose Fabry Disease in Clinical Pratice","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2020.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}